-
Mashup Score: 0
The FDA has granted an emergency use authorization for the monoclonal antibody vilobelimab in the treatment of patients with COVID-19 who have undergone ventilation or are on life support, according to a press release from the agency.
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Novel Drug Authorized for Critically Ill COVID-19 Patients - 1 year(s) ago
FDA grants EUA to anti-C5a antibody for patients on mechanical ventilation, ECMO
Source: www.medpagetoday.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
Novel Drug #Vilobelimab (#Gohibic) Authorized for Critically Ill #COVID-19 Patients — @US_FDA grants #EUA to #AntiC5aAntibody for patients on mechanical ventilation, #ECMO https://t.co/lmoyjd4hqJ @medpagetoday
-
-
Mashup Score: 3
Treatment with vilobelimab reduced mortality at 28 to 60 days in patients with severe COVID-19 pneumonia without increasing infections, according to data presented at the European Respiratory Society International Congress.Vilobelimab (InflaRx) is a first-in-class monoclonal antibody that targets the complement activation product C5a that preserves the membrane attack complex.
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
Among patients with severe #COVID19 #pneumonia, treatment with #vilobelimab reduced mortality at 28 to 60 days without increasing infections, according to data presented at #ERSCongress @InfectDisNews #PulmCC https://t.co/3rrtNJCEki
-
-
Mashup Score: 0
Treatment with vilobelimab reduced mortality at 28 to 60 days in patients with severe COVID-19 pneumonia without increasing infections, according to data presented at the European Respiratory Society International Congress.Vilobelimab (InflaRx) is a first-in-class monoclonal antibody that targets the complement activation product C5a that preserves the membrane attack complex.
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
Among patients with severe #COVID19 #pneumonia, treatment with #vilobelimab reduced mortality at 28 to 60 days without increasing infections, according to data presented at #ERSCongress @InfectDisNews #PulmCC https://t.co/8o1fDmWG5e
-
Among patients with severe #COVID19 #pneumonia, treatment with #vilobelimab reduced mortality at 28 to 60 days without increasing infections, according to data presented at #ERSCongress @InfectDisNews #PulmCC https://t.co/zg0902BZzF
-
ICYMI: The @US_FDA has granted an emergency use authorization for the monoclonal antibody #vilobelimab in the treatment of patients with #COVID19 who have undergone ventilation or are on life support https://t.co/0eAfg6QmJ4